Ads
related to: prostate cancer drug lupron medication names chart for women side effects- Case Studies
Review real case studies
with real patients.
- Sign Up for Updates
Sign up to receive the latest data,
case studies, and resources.
- Contact Us
Contact our representatives
for product and reimbursement info.
- Find an Imaging Site
Locate the nearest imaging site
or contact customer service.
- Case Studies
goodrx.com has been visited by 100K+ users in the past month
Ranked at No. 20 on the 2020 Disruptor 50 list. - CNBC
Search results
Results from the WOW.Com Content Network
Lupron injection was approved by the FDA for treatment of advanced prostate cancer on 9 April 1985. [45] [4] [43] [44] Lupron depot for monthly intramuscular injection was approved by the FDA for palliative treatment of advanced prostate cancer on 26 January 1989. [8]
Androgen deprivation therapy (ADT), also called androgen ablation therapy or androgen suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require androgen hormones, such as testosterone, to grow. ADT reduces the levels of androgen hormones, with drugs or surgery, to prevent ...
Flutamide, sold under the brand name Eulexin among others, is a nonsteroidal antiandrogen (NSAA) which is used primarily to treat prostate cancer. [9] [10] It is also used in the treatment of androgen-dependent conditions like acne, excessive hair growth, and high androgen levels in women. [11]
Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...
[78] [79] [80] Of the SAAs, CPA is the only one that has been widely used in the treatment of prostate cancer. [28]: 488 As antiandrogens, the SAAs have largely been replaced by the NSAAs and are now rarely used in the treatment of prostate cancer, due to the superior selectivity, efficacy, and tolerability profiles of NSAAs.
The side effects of cyproterone acetate (CPA), a steroidal antiandrogen and progestin, including its frequent and rare side effects, have been studied and characterized.It is generally well-tolerated and has a mild side-effect profile, regardless of dosage, when it used as a progestin or antiandrogen in combination with an estrogen such as ethinylestradiol or estradiol valerate in women.